[go: up one dir, main page]

WO2008126886A1 - インドール又はインドリン誘導体 - Google Patents

インドール又はインドリン誘導体 Download PDF

Info

Publication number
WO2008126886A1
WO2008126886A1 PCT/JP2008/057056 JP2008057056W WO2008126886A1 WO 2008126886 A1 WO2008126886 A1 WO 2008126886A1 JP 2008057056 W JP2008057056 W JP 2008057056W WO 2008126886 A1 WO2008126886 A1 WO 2008126886A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
disorder
double bond
indole
sleep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/057056
Other languages
English (en)
French (fr)
Inventor
Toshio Nakamura
Dai Nozawa
Makoto Tatsuzuki
Hiroshi Ohta
Tomoko Tamita
Seiji Masuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2008126886A1 publication Critical patent/WO2008126886A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

式（１） ｛式（１）中、波線を含む二重線は、単結合又は二重結合を示し、 Ｑは、下記構造式（Ａ）又は（Ｂ）で表される基を示し、 Ｒは、Ｃ１～Ｃ６アルキル；－Ｃ（Ｏ）Ｒ４等を示し、 Ｒ１は、Ｃ１～Ｃ６アルキル等を示し、 Ｒ２及びＲ３は、同一又は異なって、Ｃ１～Ｃ６アルキル又はＣ３～Ｃ８環状アルキル等を示す。｝で表されるヒスタミンＨ３受容体拮抗作用を有する新規なインドール若しくはインドリン誘導体、又はその医薬上許容される塩、又はこれらを有効成分として含有する医薬は、認知症、アルツハイマー病、注意欠陥・多動性症、統合失調症、摂食障害、肥満、糖尿病、高脂血症、睡眠障害、ナルコレプシー、睡眠時無呼吸症候群、概日リズム障害、うつ病若しくはアレルギー性鼻炎等の疾患の予防又は治療に有用である。 　　　　　　　
PCT/JP2008/057056 2007-04-12 2008-04-10 インドール又はインドリン誘導体 Ceased WO2008126886A1 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007104536 2007-04-12
JP2007-104536 2007-04-12
JP2007-281814 2007-10-30
JP2007281814 2007-10-30

Publications (1)

Publication Number Publication Date
WO2008126886A1 true WO2008126886A1 (ja) 2008-10-23

Family

ID=39863982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/057056 Ceased WO2008126886A1 (ja) 2007-04-12 2008-04-10 インドール又はインドリン誘導体

Country Status (1)

Country Link
WO (1) WO2008126886A1 (ja)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008302570B2 (en) * 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2017195703A1 (ja) * 2016-05-09 2017-11-16 日本曹達株式会社 環状アミン化合物および有害生物防除剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998043956A1 (en) * 1997-03-31 1998-10-08 Eisai Co., Ltd. 1,4-substituted cyclic amine derivatives
JPH10512893A (ja) * 1995-01-31 1998-12-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗精神病性の４−（１ｈ−インドリル−１−イル）−１−置換ピペリジン誘導体
JP2006503056A (ja) * 2002-09-18 2006-01-26 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニスト、その製造および治療用使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10512893A (ja) * 1995-01-31 1998-12-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗精神病性の４−（１ｈ−インドリル−１−イル）−１−置換ピペリジン誘導体
WO1998043956A1 (en) * 1997-03-31 1998-10-08 Eisai Co., Ltd. 1,4-substituted cyclic amine derivatives
JP2006503056A (ja) * 2002-09-18 2006-01-26 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニスト、その製造および治療用使用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008302570B2 (en) * 2007-09-20 2012-05-31 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8258156B2 (en) 2007-09-20 2012-09-04 Irm Llc Compounds and compositions as modulators of GPR119 activity
WO2017195703A1 (ja) * 2016-05-09 2017-11-16 日本曹達株式会社 環状アミン化合物および有害生物防除剤
JPWO2017195703A1 (ja) * 2016-05-09 2019-02-14 日本曹達株式会社 環状アミン化合物および有害生物防除剤
US11178872B2 (en) 2016-05-09 2021-11-23 Nippon Soda Co., Ltd. Cyclic amine compound and pest control agent

Similar Documents

Publication Publication Date Title
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
NO20083434L (no) Benzamid- og heteroarenderivater
NO20076060L (no) Piperidin-4-yl-amidderivater og deres anvendelse som SST-reseptor subtype 5-antagonister
NO20062370L (no) Amidderivater
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
ATE428422T1 (de) Piperidin-derivate als ccr3-antagonisten
SE0402735D0 (sv) Novel compounds
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
CA2702933A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
GB0413087D0 (en) Therapeutic compounds
NO20076695L (no) Nye MCHR1-antagonister og deres anvendelse for behandling av MCHR1-medierte tilstander og forstyrrelser
MY173546A (en) Phenylpyrazole derivatives
DE602006009095D1 (en) Diacylglycerol-acyltransferase-hemmer
WO2008006795A3 (en) Indole compounds
MX2011008336A (es) Derivados de dihidroquinolinona.
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
WO2007111983A3 (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08740157

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08740157

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP